Evidence map›Paper›PMID 42131127›Full record

ArticleFrontiers in bioinformatics2026

Deepasree K, Sudha Ramaiah

Abstract read
In one paragraph

Article in Frontiers in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Deepasree KMedical and Biological Computing Laboratory, School of Bio Sciences and Technology (SBST), Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, India.
Sudha RamaiahMedical and Biological Computing Laboratory, School of Bio Sciences and Technology (SBST), Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Natural compounds present in medicinal plants have made significant contributions to the field of drug development due to their diverse therapeutic properties. One such crucial application of the phytocompounds is to suppress the survival of pathogenic microbes that withstand the current treatment regimens. Methods: Following an Results: Xambioona and Licoisoflavone B exhibited good binding affinity values of -10.4 kcal/mol and -8.7 kcal/mol with the AlphaFold model of ActA protein, respectively. Discussion: Molecular dynamics (MD) simulation for a timescale of 100 ns and binding free analysis revealed Licoisoflavone B to be a promising phytocompound due to its overall conformational stability.

Indexed as

ab initio modellingLipinski’s ruleliquoricephytocompoundsvirtual screeningvirulence protein

Identifiers

PMID42131127
PMCPMC13161068

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.